SPIA
LUCD icon

Steward Partners Investment Advisory’s Lucid Diagnostics LUCD Stock Holding History

Steward Partners Investment Advisory’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Buy
+2
New +$2 ﹤0.01% 4648

Other funds holding LUCD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Steward Partners Investment Advisory's LUCD Position: Q2 2026 in Review

Steward Partners Investment Advisory opened a new position in Lucid Diagnostics (LUCD) in Q2 2026: 2 shares worth $2. The stake represents ﹤0.01% of the portfolio and ranks #4648 among its holdings.

86 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Steward Partners Investment Advisory held 2 shares of Lucid Diagnostics worth $2 as of Q2 2026.
  • Lucid Diagnostics was a new Steward Partners Investment Advisory position in Q2 2026.
  • Lucid Diagnostics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #4648 holding.
  • 86 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.